Limerick, Ireland

Paul Conroy

This inventor holds 1 USPTO granted patent. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Conroy. Retrieved from https://idiyas.com/inventor/paul-conroy-n2j6nexb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Paul Conroy: Innovator in Biopharmaceuticals

Introduction

Paul Conroy is a notable inventor based in Limerick, Ireland. He has made significant contributions to the field of biopharmaceuticals, particularly in the characterization and purification of proteins. His work is essential for advancing medical treatments and therapies.

Latest Patents

Paul Conroy holds a patent titled "Methods of Characterizing and Purifying VEGF Receptor Fusion Protein." This patent reflects his expertise in biochemistry and his commitment to improving therapeutic proteins.

Career Highlights

Conroy is currently employed at Regeneron Pharmaceuticals, Inc., a leading biotechnology company known for its innovative approaches to drug development. His role at Regeneron allows him to work on cutting-edge research that has the potential to impact patient care significantly.

Collaborations

Throughout his career, Paul has collaborated with esteemed colleagues, including John Crowley and Marguerita McCarthy. These partnerships have fostered a collaborative environment that enhances the quality of research and innovation.

Conclusion

Paul Conroy's contributions to the field of biopharmaceuticals exemplify the impact of dedicated inventors in advancing medical science. His work continues to inspire future innovations in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…